Good agreement between physician and self-reported hormone therapy data in a case–control study

详细信息    查看全文

• 作者：S. Kropp ; T. Terboven ; J. Hedicke ; E. Mutschelknauss ; T. Slanger ; W. Braendle ; J. Berger ; J. Chang-Claude ; D. Flesch-Janys
• 关键词：Breast neoplasms ; Hormone replacement therapy ; Estrogen replacement therapy ; Postmenopause ; Validation studies ; Case– ; control studies
• 刊名：Journal of Clinical Epidemiology
• 出版年：2007
• 出版时间：December 2007
• 年：2007
• 卷：60
• 期：12
• 页码：1280-1287
• 全文大小：147 K

文摘

In a population-based case–control study examining the effects of postmenopausal hormone therapy (HT) on breast cancer risk, the authors conducted a validation study comparing prescription data from gynecologists with self-reports.

ss=""h4"">Study Design and Setting

The study was conducted in the Rhein-Neckar and Hamburg regions of Germany from 2002 to 2005. A total of 224 cases and 225 controls, stratified by region, age, and hormone use were randomly selected for the validation study.

ss=""h4"">Results

For ever/never use 88.2 % agreement was seen, and agreement for ever/never use by type of HT was 80.6 % , 80.3 % , and 90.5 % for mono-estrogen, cyclical combined, and continuous combined therapy, respectively. The intraclass correlation coefficient (ICC) for duration of use was high, 0.82 (95 % confidence interval [CI]: 0.77, 0.85), as were the ICCs for age at first and last use, 0.88 (95 % CI: 0.85, 0.91) and 0.98 (95 % CI: 0.97, 0.98). Despite the exceptionally high number of different HT prescriptions available in Germany, comparison of exact brand name resulted in perfect agreement for 50.2 % of participants, partial agreement for 29.3 % , and no agreement for 20.7 % . In general, agreement was not differential by disease status.

ss=""h4"">Conclusion

Overall, the self-reported HT of the study participants corresponded well with physicians' reports.